Overview

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Status:
NOT_YET_RECRUITING

Trial end date:
2029-06-30

Target enrollment:

Participant gender:

Summary

This study is being done to answer the following questions: * Is the new cell therapy, GCAR1, safe to use, and what effects does it have on cancer? * What is the right dose of the treatment which could be used in future studies?

Phase:

PHASE1

Details

Lead Sponsor:

Canadian Cancer Trials Group

Treatments:

Cyclophosphamide
fludarabine